doi: 10.3390/agronomy14030453 212 SamotaMKSharmaMKaurKSaritaYadavDKPandeyAKet al
1 9 10 But animal efficacy translating to human benefit is the exception, not the rule, in drug development
The current study revealed that plasma ALC levels were approximately 42% lower in individuals with hypercholesterolemia compared to those without hypercholesterolemia
[DOI] [PubMed] [Google Scholar] 51.Decramer M., Rutten-van M.M., Dekhuijzen P.N.R., Troosters T., van Herwaarden C., Pellegrino R., van Schayck C.P.O., Olivieri D., Donno M.D., De Backer W., et al
Although these trials primarily enrolled individuals with relatively low DKD risk and were not designed to evaluate kidney outcomes specifically, exploratory analyses consistently indicated slower kidney disease progression across diverse eGFR and albuminuria levels [39-44]
Hum Reprod (2000) 15(6):12505